Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Page 1
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Flume PA, et al. Among authors: wagener js. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24. J Cyst Fibros. 2018. PMID: 28651844 Free article.
Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both compared with baseline measured just prior to the PEx. RESULTS: Fewer patients receiving ivacaftor experienced a PEx than patients receiving …
Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both …
Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW. Sawicki GS, et al. Among authors: wagener js. Am J Respir Crit Care Med. 2015 Oct 1;192(7):836-42. doi: 10.1164/rccm.201503-0578OC. Am J Respir Crit Care Med. 2015. PMID: 26132840
However, whether these improvements reflect a change in disease trajectory cannot be determined without longer-term analyses with an appropriate comparator population. OBJECTIVES: To examine, over a 3-year period, whether ivacaftor therapy affects pulmonary function and nu …
However, whether these improvements reflect a change in disease trajectory cannot be determined without longer-term analyses with an …
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE, Schechter MS, Wagener JS, Morgan WJ, Pasta DJ, Elkin EP, Konstan MW; Investigators of the Epidemiologic Study of Cystic Fibrosis. Regelmann WE, et al. Among authors: wagener js. Pediatr Pulmonol. 2013 Jul;48(7):649-57. doi: 10.1002/ppul.22658. Epub 2012 Sep 4. Pediatr Pulmonol. 2013. PMID: 22949088 Free PMC article.
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis....
The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that resp …
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS, Rasouliyan L, VanDevanter DR, Pasta DJ, Regelmann WE, Morgan WJ, Konstan MW; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Wagener JS, et al. Pediatr Pulmonol. 2013 Jul;48(7):666-73. doi: 10.1002/ppul.22652. Epub 2012 Aug 8. Pediatr Pulmonol. 2013. PMID: 22888106 Free PMC article.
METHODS: We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long-term lung function change associated with clinician reported PExs. ...
METHODS: We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long- …
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF. Schechter MS, et al. Among authors: wagener js. J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16. J Pediatr. 2009. PMID: 19608199 Free PMC article.
Shifting patterns of inhaled antibiotic use in cystic fibrosis.
Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF). Moskowitz SM, et al. Among authors: wagener js. Pediatr Pulmonol. 2008 Sep;43(9):874-81. doi: 10.1002/ppul.20873. Pediatr Pulmonol. 2008. PMID: 18668689
CONCLUSIONS: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CF population. The effects of these usage patterns on long-term clinical outcomes and em …
CONCLUSIONS: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive managemen …
Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Sontag MK, et al. Among authors: wagener js. J Pediatr. 2005 Sep;147(3 Suppl):S83-8. doi: 10.1016/j.jpeds.2005.08.005. J Pediatr. 2005. PMID: 16202790
Finally, infants with persistent hypertrypsinogenemia and borderline sweat test results need long-term follow-up....
Finally, infants with persistent hypertrypsinogenemia and borderline sweat test results need long-term follow-up....
Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.
Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Rodman DM, et al. Among authors: wagener js. Am J Respir Crit Care Med. 2005 Mar 15;171(6):621-6. doi: 10.1164/rccm.200403-404OC. Epub 2004 Dec 10. Am J Respir Crit Care Med. 2005. PMID: 15591474
This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ distinctly from survivors of long-term CF diagnosed as children....
This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ d …
Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group.
Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Wagener JS, et al. J Pediatr. 1998 Oct;133(4):486-91. doi: 10.1016/s0022-3476(98)70055-1. J Pediatr. 1998. PMID: 9787685 Clinical Trial.
The purpose of this study was to assess the delivery to the lungs and the short-term safety of recombinant human deoxyribonuclease (rhDNase, Pulmozyme) in children with cystic fibrosis younger than 5 years of age compared with older children. ...During this time adverse ev …
The purpose of this study was to assess the delivery to the lungs and the short-term safety of recombinant human deoxyribonuclease (r …
12 results